William Blair analyst Brandon Vazquez has maintained their bullish stance on GKOS stock, giving a Buy rating on October 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Glaukos’s potential for sustained growth. The company’s third-quarter sales exceeded expectations by 9%, largely driven by the strong performance of iDose, which has seen increased adoption and utilization. This success led management to raise their 2025 revenue guidance, indicating confidence in continued growth.
Additionally, the upcoming launch of Epioxa, with its compelling pricing and existing patient base, is expected to be another significant growth driver. Despite anticipated short-term disruptions, the robust product pipeline and attractive average selling prices suggest that Glaukos’s business has the potential to expand significantly. The market’s positive reaction, with shares rising by approximately 20%, further supports the outlook for durable long-term growth, justifying the Buy rating.
According to TipRanks, Vazquez is an analyst with an average return of -2.9% and a 30.30% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., Align Tech, and Glaukos.
In another report released on October 27, Stifel Nicolaus also maintained a Buy rating on the stock with a $115.00 price target.